High-Frequency Audiometric Monitoring Strategies for

Ear and Hearing 15, 232-239 DOI: 10.1097/00003446-199406000-00004

Citation Report

CITATION REPORT

#	ARTICLE	IF	CITATIONS
1	Monitoring chemotherapy-induced hearing loss in children. European Journal of Cancer, 1996, 32, 1185-1188.	2.8	4
2	Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. British Journal of Cancer, 1998, 77, 1355-1362.	6.4	284
3	Cumulative toxicities from cisplatin therapy and current cytoprotective measures. Cancer Treatment Reviews, 1998, 24, 265-281.	7.7	98
4	Vancomycin administration in continuous ambulatory peritoneal dialysis: The risk of ototoxicity. Otolaryngology - Head and Neck Surgery, 1998, 118, 551-558.	1.9	26
5	Aging and High-Frequency Hearing Sensitivity. Journal of Speech, Language, and Hearing Research, 1998, 41, 1061-1072.	1.6	43
6	Basal Cochlear Lesions Result in Increased Amplitude of Otoacoustic Emissions. Audiology and Neuro-Otology, 1998, 3, 361-372.	1.3	26
7	Evaluation of Organic Solvent Ototoxicity by the Upper Limit of Hearing. Archives of Environmental Health, 1999, 54, 341-346.	0.4	28
8	Selective Loss of Inner Hair Cells and Type-I Ganglion Neurons in Carboplatin-Treated Chinchillas: Mechanisms of Damage and Protection. Annals of the New York Academy of Sciences, 1999, 884, 152-170.	3.8	85
9	Third Place—Resident Clinical Science Award 1998: Effects of <i>Cis</i> â€Platinum Chemotherapy on Otoacoustic Emissions: The Development of an Objective Screening Protocol. Otolaryngology - Head and Neck Surgery, 1999, 121, 693-701.	1.9	82
10	Global Problem of Drugâ€Induced Hearing Loss. Annals of the New York Academy of Sciences, 1999, 884, 1-14.	3.8	66
11	An Individualized, Sensitive Frequency Range for Early Detection of Ototoxicity. Ear and Hearing, 1999, 20, 497-505.	2.1	111
12	Ototoxicity: An Argument for Evaluation of the Cochlea in Safety Testing in Animals. Toxicologic Pathology, 2000, 28, 137-141.	1.8	13
13	Extended high-frequency ototoxicity induced by the first administration of cisplatinâ~†. Otolaryngology - Head and Neck Surgery, 2000, 122, 828-833.	1.9	37
14	Ototoxicidad medicamentosa. EMC - OtorrinolaringologÃa, 2000, 29, 1-12.	0.0	1
15	Feasibility of establishing an early indicator for ototoxicity in children using otoacoustic emissions. Asia Pacific Journal of Speech Language and Hearing, 2001, 6, 117-127.	0.2	2
16	Pifithrin- \hat{I}_{\pm} supresses p53 and protects cochlear and vestibular hair cells from cisplatin-induced apoptosis. Neuroscience, 2003, 120, 191-205.	2.3	149
17	Perioperative Hearing Impairment. Anesthesiology, 2003, 98, 241-257.	2.5	40
18	Rate of False-Positive Results for Threshold Shifts during Initial Treatment with Aminoglycosides. Orl, 2004, 66, 105-110.	1.1	2

2

#	Article	IF	CITATIONS
19	Evaluation of insert earphones for high-frequency bedside ototoxicity monitoring. Journal of Rehabilitation Research and Development, 2004, 42, 353.	1.6	11
20	Test-Retest Reliability of Pure-Tone Thresholds from 0.5 to 16 kHz using Sennheiser HDA 200 and Etymotic Research ER-2 Earphones. Ear and Hearing, 2004, 25, 127-132.	2.1	84
21	Hearing health and care: The need for improved hearing loss prevention and hearing conservation practices. Journal of Rehabilitation Research and Development, 2005, 42, 45.	1.6	88
22	Distortion product otoacoustic emissions: An objective technique for the screening of hearing loss in children treated with platin derivatives. International Journal of Audiology, 2006, 45, 337-343.	1.7	32
23	Hearing Loss in Patients With Vestibulotoxic Reactions to Gentamicin Therapy. JAMA Otolaryngology, 2006, 132, 253.	1.2	40
24	Auditory monitoring in ototoxicity. Brazilian Journal of Otorhinolaryngology, 2006, 72, 836-844.	1.0	22
25	Repeatability of High-Frequency Distortion-Product Otoacoustic Emissions in Normal-Hearing Adults. Ear and Hearing, 2006, 27, 466-479.	2.1	46
26	Early Changes in Auditory Function As a Result of Platinum Chemotherapy: Use of Extended High-Frequency Audiometry and Evoked Distortion Product Otoacoustic Emissions. Journal of Clinical Oncology, 2007, 25, 1190-1195.	1.6	189
27	Recovery from cisplatin-induced ototoxicity: A case report and review. International Journal of Pediatric Otorhinolaryngology, 2007, 71, 1631-1638.	1.0	25
28	Hearing loss in children with very low birth weight: current review of epidemiology and pathophysiology. Archives of Disease in Childhood: Fetal and Neonatal Edition, 2008, 93, F462-F468.	2.8	125
29	Ototoxicity of Toluene and Styrene: State of Current Knowledge. Critical Reviews in Toxicology, 2008, 38, 127-170.	3.9	42
30	High Frequency Audiometric Study in Cancer-Cured Patients Treated with Cisplatin. Brazilian Journal of Otorhinolaryngology, 2008, 74, 382-390.	1.0	9
31	Factors Affecting Sensitivity of Distortion-Product Otoacoustic Emissions to Ototoxic Hearing Loss. Ear and Hearing, 2008, 29, 875-893.	2.1	52
32	Acute idiopathic sensorineural hearing impairment at frequency exceeding 8 kHz. Acta Oto-Laryngologica, 2010, 130, 1141-1146.	0.9	5
33	Evaluation of Audiometric Threshold Shift Criteria for Ototoxicity Monitoring. Journal of the American Academy of Audiology, 2010, 21, 301-314.	0.7	21
34	Long term hearing degeneration after platinum-based chemotherapy in childhood. International Journal of Audiology, 2010, 49, 765-771.	1.7	43
35	Aminoglycoside antibiotics cochleotoxicity in paediatric cystic fibrosis (CF) patients: A study using extended high-frequency audiometry and distortion product otoacoustic emissions. International Journal of Audiology, 2011, 50, 112-122.	1.7	42
36	Cell Death in the Inner Ear. , 0, , 182-193.		3

#	Article	IF	CITATIONS
37	A New Method to Analyze Distortion Product Otoacoustic Emissions (DPOAEs) in the High-Frequency Range Up to 18 kHz Using Windowed Periodograms. IEEE Transactions on Biomedical Engineering, 2011, 58, 2369-2377.	4.2	10
38	Distortion product otoacoustic emission for the screening of cochlear damage in children treated with cisplatin. Laryngoscope, 2011, 121, 1081-1084.	2.0	12
39	Ototoxicity Monitoring: Program Approaches and Considerations. Seminars in Hearing, 2011, 32, 248-261.	1.2	3
40	Symptom Reporting Compared with Audiometry for the Detection of Cochleotoxicity in Patients on Long-Term Aminoglycoside Therapy. Annals of Pharmacotherapy, 2011, 45, 590-595.	1.9	1
41	High-Frequency Pure-Tone Audiometry in Children: A Test–Retest Reliability Study Relative to Ototoxic Criteria. Ear and Hearing, 2012, 33, 104-111.	2.1	40
42	Multivariate DPOAE metrics for identifying changes in hearing: Perspectives from ototoxicity monitoring. International Journal of Audiology, 2012, 51, S51-S62.	1.7	22
43	Human ultrasonic hearing is induced by a direct ultrasonic stimulation of the cochlea. Neuroscience Letters, 2013, 539, 71-76.	2.1	11
44	OtoID: New extended frequency, portable audiometer for ototoxicity monitoring . Journal of Rehabilitation Research and Development, 2013, 50, 997-1006.	1.6	14
45	Gentamicin Concentration Gradients in Scala Tympani Perilymph following Systemic Applications. Audiology and Neuro-Otology, 2013, 18, 383-391.	1.3	20
46	Comparison of the Effectiveness of Monitoring Cisplatin-Induced Ototoxicity with Extended High-Frequency Pure-Tone Audiometry or Distortion-Product Otoacoustic Emission. Korean Journal of Audiology, 2014, 18, 58.	0.7	16
47	Trauma-Associated Tinnitus. Journal of Head Trauma Rehabilitation, 2014, 29, 432-442.	1.7	37
48	Concordance between the chang and the International Society of Pediatric Oncology (<scp>SIOP</scp>) ototoxicity grading scales in patients treated with cisplatin for medulloblastoma. Pediatric Blood and Cancer, 2014, 61, 601-605.	1.5	36
49	Extended high-frequency (9–20 kHz) audiometry reference thresholds in 645 healthy subjects. International Journal of Audiology, 2014, 53, 531-545.	1.7	101
50	Cisplatin-Induced Ototoxicity: Effects, Mechanisms and Protection Strategies. Toxics, 2015, 3, 268-293.	3.7	98
51	Heat Shock Protein-Mediated Protection Against Cisplatin-Induced Hair Cell Death. JARO - Journal of the Association for Research in Otolaryngology, 2015, 16, 67-80.	1.8	42
52	Cisplatin-Associated Ototoxicity: A Review for the Health Professional. Journal of Toxicology, 2016, 2016, 1-13.	3.0	92
53	Long-term audiologic follow-up of carboplatin-treated children with retinoblastoma. Ophthalmic Genetics, 2017, 38, 74-78.	1.2	7
54	Fixed-Level Frequency Threshold Testing for Ototoxicity Monitoring. Ear and Hearing, 2017, 38, e369-e375.	2.1	18

	Сітатіо	CITATION REPORT	
#	Article	IF	CITATIONS
55	Drug-Induced Ototoxicity: Diagnosis and Monitoring. Drug Safety, 2018, 41, 451-464.	3.2	48
56	Using tablet-based technology to deliver time-efficient ototoxicity monitoring. International Journal of Audiology, 2018, 57, S78-S86.	1.7	14
57	The use of uHearâ,,¢ to screen for hearing loss in older patients with cancer as part of a comprehensive geriatric assessment. Acta Clinica Belgica, 2018, 73, 132-138.	1.2	18
58	Ototoxicity: A Challenge in Diagnosis and Treatment. Journal of Audiology and Otology, 2018, 22, 59-68.	0.8	94
59	Auditory Outcomes in Patients Who Received Proton Radiotherapy for Craniopharyngioma. American Journal of Audiology, 2018, 27, 306-315.	1.2	4
60	Monitoring Protocols for Cochlear Toxicity. Seminars in Hearing, 2019, 40, 122-143.	1.2	14
61	A Review of Cisplatin-Associated Ototoxicity. Seminars in Hearing, 2019, 40, 108-121.	1.2	33
62	Monitoring Hearing in an Infectious Disease Clinic with mHealth Technologies. Journal of the American Academy of Audiology, 2019, 30, 482-492.	0.7	12
63	Looking beyond the audiogram in ototoxicity associated with platinum-based chemotherapy. Cancer Chemotherapy and Pharmacology, 2020, 85, 245-250.	2.3	21
64	Hearing in Schoolchildren After Neonatal Exposure to a High-Dose Gentamicin Regimen. Pediatrics, 2020, 145, e20192373.	2.1	4
65	Extended High Frequency Audiometry for Revealing Sudden Sensory Neural Hearing Loss in Acute Tinnitus Patients. International Archives of Otorhinolaryngology, 2021, 25, e413-e415.	0.8	5
66	Functional Impacts of Aminoglycoside Treatment on Speech Perception and Extended High-Frequency Hearing Loss in a Pediatric Cystic Fibrosis Cohort. American Journal of Audiology, 2021, 30, 834-853.	1.2	19
67	Ototoxic effects of antineoplastic drugs: a systematic review. Brazilian Journal of Otorhinolaryngology, 2022, 88, 130-140.	1.0	2
68	Detection of unknown ototoxic adverse drug reactions: an electronic healthcare record-based longitudinal nationwide cohort analysis. Scientific Reports, 2021, 11, 14045.	3.3	6
69	Otoacoustic Emissions as a Diagnostic Tool in a Clinical Context. , 2008, , 421-460.		5
70	Extended High-Frequency Ototoxicity Induced by the First Administration of Cisplatin. Otolaryngology - Head and Neck Surgery, 2000, 122, 828-833.	1.9	2
71	Early Detection of Ototoxicity Using 1/6th-Octave Steps. Journal of the American Academy of Audiology, 2003, 14, 444-450.	0.7	35
72	Monitoramento auditivo na ototoxidade. Revista Brasileira De Otorrinolaringologia, 2006, 72, 836-844.	0.2	18

#	Article	IF	CITATIONS
73	Estudo audiometrico de alta fraquência em pacientes curados de câncer tratados com cisplatina. Revista Brasileira De Otorrinolaringologia, 2008, 74, 382-390.	0.2	11
74	Auditory and vestibular dysfunction associated with blast-related traumatic brain injury. Journal of Rehabilitation Research and Development, 2009, 46, 797.	1.6	182
75	Antiinfektiöse Therapie. , 2000, , 868-1037.		0
76	Antiinfektiöse Therapie. , 2003, , 929-1109.		0
77	Effectiveness of medical interventions implemented during ototoxicity monitoring to prevent further deterioration of hearing thresholds. UR UCT Undergraduate Research, 2016, 1, .	0.0	0
78	Monitorización de la ototoxicidad por cisplatino Revista ORL, 2016, .	0.1	0
80	Identifying Subclinical Hearing Loss: Extended Audiometry and Word Recognition in Noise. Audiology and Neuro-Otology, 2022, 27, 217-226.	1.3	6
82	Semi-automated quantification of hair cells in the mature mouse utricle. Hearing Research, 2022, 416, 108429.	2.0	2
83	Cisplatin-associated ototoxicity: perspectives from a single institution cervical cancer cohort and implications for developing a locally responsive monitoring programme in a public healthcare setting. BMC Health Services Research, 2022, 22, .	2.2	4
85	Extended high-frequency audiometric analyses of tinnitus patients exhibiting normal hearing on conventional pure-tone audiometry. Acta Oto-Laryngologica, 2022, 142, 579-584.	0.9	0
87	Hearing assessment and treatment outcome in ENT tuberculosis at a tertiary hospital in India. The Egyptian Journal of Otolaryngology, 2023, 39, .	0.3	0
88	What's New in Ototoxicity Management?. Perspectives of the ASHA Special Interest Groups, 2024, 9, 113-123.	0.8	0

CITATION REPORT